Outcomes in the PSM cohort:
Colchicine was associated with a significant reduced risk of AF
recurrence (HR 0.71, 95% CI [0.53, 0.96], p=0.026) (Figure 2). Mean
time to AF recurrence in days were 550 days (247, 1,174) in colchicine
group vs 331 days (200, 674) in no colchicine group. Colchicine use was
associated with decreased AF recurrence in patients with paroxysmal AF
(HR 0.70, CI 0.50-0.98, p=0.036) but not persistent AF (HR 0.79, CI
0.39-1.59, p=0.5).